drugset / Trial / NCT01719523
Open-Trial of EPI-743 for Adults With Tourette Syndrome
Phase 1
Completed
10 enrolled
Yale University
Edison Pharmaceuticals Inc · collabRembrandt Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the effects of EPI-743 on tic severity in adults with Tourette syndrome.
Timeline
- Start
- 2012-10
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vatiquinone | Small molecule | 300 mg | Oral |